Ascletis Pharma halves H1 2025 net loss, invests in R&D

Ascletis Pharma Inc. reported a 32.5% decrease in its loss for the six months ended June 30, 2025, falling to RMB87.951 million from RMB130.318 million in the prior year. Total income surged by 111.4% to RMB103.577 million from RMB49.004 million. Research and development costs increased by 10.9% to RMB146.812 million, reflecting continued investment in its metabolic disease pipeline.

The reduction in losses was attributed to enhanced spending efficiency on clinical and preclinical projects, alongside a rise in other income and gains. The company's cash and cash equivalents, along with other capital resources, totaled approximately RMB1,827.9 million as of June 30, 2025, which is projected to sustain operations and R&D activities until 2029.

Key pipeline progress includes promising Phase Ib results for ASC30 oral and SQ injection for obesity, initiation of ASC50 Phase I clinical study for psoriasis, and successful Phase III results for ASC40 in treating acne. The Group plans to seek commercial partners for its ASC40 acne program and license-out opportunities for ASC61 for solid tumors.